Loading...
Market
Will Recursion Pharmaceuticals ($RXRX) initiate Phase 3 trial for REC-994 by March 31, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
ClinicalTrials.gov and Recursion Pharmaceuticals press releases
Story
Recursion Pharmaceuticals ($RXRX) Announces Positive Phase 2 Results for REC-994 in CCM
Sep 3, 2024, 12:08 PM
Recursion Pharmaceuticals ($RXRX) has announced positive Phase 2 topline results for REC-994, a first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The drug met its primary endpoint of safety and tolerability. Additionally, magnetic resonance imaging (MRI)-based secondary efficacy endpoints showed a trend towards reduced lesion volume. Despite these promising results, some investors remain cautious about the AI drug discovery developer's future prospects.
View original story
Similar markets
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
